Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
Eli Lilly and Company
Intuitive Surgical
Memorial Sloan Kettering Cancer Center
Stemline Therapeutics, Inc.
Perspectum
AstraZeneca
Maastricht University Medical Center
Incepta Pharmaceuticals Ltd
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
Ostergotland County Council, Sweden
Endeavor Health
Alliance for Clinical Trials in Oncology
Universitätsmedizin Mannheim
Silesian Centre for Heart Diseases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University Health Network, Toronto
National Taipei University of Nursing and Health Sciences
The Affiliated Hospital of Qingdao University
Hoffmann-La Roche
Odense University Hospital
RemeGen Co., Ltd.
Stanford University
RenJi Hospital
State University of New York - Upstate Medical University
University of Chicago
Novartis
TaiHao Medical Inc.
pfm medical gmbh
Maastricht University Medical Center
Albert Einstein Healthcare Network
European Institute of Oncology
IRCCS San Raffaele
Medipol University
Instituto de Investigación Hospital Universitario La Paz
Centro di Riferimento Oncologico - Aviano
Fondation Hôpital Saint-Joseph
Insel Gruppe AG, University Hospital Bern
University of Rome Tor Vergata
TaiHao Medical Inc.
BioNumerik Pharmaceuticals, Inc.
Myriad Genetic Laboratories, Inc.
Syndax Pharmaceuticals
Sun Yat-sen University
NSABP Foundation Inc
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Syndax Pharmaceuticals